Sarah Meibusch

Sarah brings over 18 years of global life science business development and management experience, 13 of those years in the human healthcare industry. She is currently a Principal in the OneVentures healthcare team. Her previous roles included 5 years scouting for Shire Pharmaceuticals, a global specialty pharmaceutical company (LON: SHP). Sarah sought technologies for Shire in Australia, New Zealand, Singapore, Taiwan, Korea and Japan including playing a key role in sourcing the $300M Fibrotech deal announced in 2015. Sarah has a strong operational understanding of the pharmaceutical and life science industries gained through senior management roles at the Progen Pharmaceuticals, The University of Queensland’s QAAFI institute, Beef CRC and Pyxis Genomics.

Sarah is a graduate of Cornell University (Masters of Professional Studies), University of Queensland (Bachelor of Agricultural Science, Biochemistry and Animal Science) and is a graduate of the Australian Institute of Company Directors (GAICD). She has also completed postgraduate courses at Harvard Business School focusing on negotiation and decision making.